The dose-response relationship between plasma insulin concentration and total glucose uptake, glucose oxidation, and glucose storage was examined in 22 healthy young volunteers by employing the euglycemic insulin clamp technique in combination with indirect calorimetry. Insulin was infused at five rates to achieve steady-state hyperinsulinemic plateaus of 62 ± 4, 103 ± 5, 170 ± 10, 423 ± 16, and 1132 ± 47 μU/ml. With increasing plasma insulin concentrations within the physiologic range, there was a linear increase in glucose uptake with a half maximally effective insulin concentration of 72 μU/ml. Glucose uptake by all tissues of the body reached 80% of its maximum value (12.6 mg/kg · min) at a plasma insulin concentration of ∼200 μU/ml. In contrast to total glucose uptake, glucose oxidation plateaued more quickly, achieved a maximum rate of only 4.0 mg/kg · min, and displayed a lower half maximally effective insulin concentration of 40 μU/ml. The increase in glucose uptake with progressively increasing plasma insulin levels was primarily the result of an increase in glucose storage, with a half maximally effective insulin concentration of 105 μU/ml and maximum rate of 8.7 mg/kg · min. Glucose storage represented over 60–70% of total glucose uptake at all insulin concentrations. After achieving maximum rates of insulin-mediated glucose uptake (plasma insulin concentration = 1132 μU/ml), hyperglycemia (+125 mg/dl) was superimposed on hyperinsulinemia to further enhance glucose transport. Under these conditions, total glucose uptake (32.5 mg/kg · min, P < 0.001) was markedly augmented but no significant increase in glucose oxidation was observed. These results indicate a true saturation of the glucose oxidation pathway. With pro-gressively increasing doses of insulin, the glucose storage represents the major route of glucose disposal.

No abstract

We studied the acute phase response, including specific cytokine production, [interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor alpha(TNF alpha)] following a single dose of Aredia (disodium pamidronate) in patients with increased bone turnover and, in vitro, the role played by specific cytokines in the acute-phase reaction which may follow the administration of aminobisphosphonates. An in vivo exploratory study was done on 24 in- and outpatients with increased bone turnover given a single intravenous dose of pamidronate 60 mg. Measurements were taken at baseline and at 24, 48, and 72 hours. The main outcome measures were changes from baseline in serum IL-1, IL-6, and TNF alpha. In addition, C-reactive protein (CRP), white blood cell count (WCC), lymphocyte count, and elastase concentration were measured. Symptomatic evaluation was made of fever, bone pain, and rigors. In vitro, whole blood from eight healthy volunteers was exposed to various concentrations of the three bisphosphonates--pamidronate, clodronate, and zoledronate. Measurements were taken immediately before and at 3, 6, and 10 hours after exposure to drugs. The main outcome measures were changes in serum IL-1, IL-6, and TNF alpha. In vivo, there was a statistically significant (P < 0.001) increase in median values of TNF alpha in all post-baseline measurements. Median values for IL-6 also showed a significant (P < 0.001) increase at 24 hours after dosing. There were no statistically significant changes in median IL-1 values. Few patients showed any change from baseline in total WCC or in lymphocyte count, but 62.5% of patients with normal range baseline values for CRP increased to above normal levels after treatment. Fourteen patients experienced fever; 2 reported rigors. There was no correlation between fever and changes in cytokines. There were no serious adverse experiences or premature discontinuations due to poor tolerability, and 91% of the patients expressed willingness to receive pamidronate again. In vitro, an increase in TNF alpha and a mild increase in IL-6 was seen with all bisphosphonates, with the greatest effects seen with the highest concentration of both pamidronate and zoledronate. No changes were observed in IL-1 with any agent. Significant changes in both TNF alpha and IL-6 were observed within 3 days of a single dose of pamidronate in patients treated for the first time confirming previous findings. However, the lack of change in IL-1 in vivo and in vitro does not support the hypothesis that this cytokine plays a major role in the acute phase reaction. The cellular mechanism of the interaction among aminobisphosphonates, IL-6, and TNF alpha requires further investigations. The results of the in vitro study are consistent with the in vivo findings.

Segmental body composition assessed by bioelectrical impedance analysis and DEXA in humans. J. Appl. Physiol. 81(6): 2580-2587, 1996.-The present study assessed the relative contribution of each body segment to whole body fat-free mass (FFM) and impedance and explored the use of segmental bioelectrical impedance analysis to estimate segmental tissue composition. Multiple frequencies of whole body and segmental impedances were measured in 51 normal and overweight women. Segmental tissue composition was independently assessed by dual-energy X-ray absorptiometry. The sum of the segmental impedance values corresponded to the whole body value (100.5 6 1.9% at 50 kHz). The arms and legs contributed to 47.6 and 43.0%, respectively, of whole body impedance at 50 kHz, whereas they represented only 10.6 and 34.8% of total FFM, as determined by dual-energy X-ray absorptiometry. The trunk averaged 10.0% of total impedance but represented 48.2% of FFM. For each segment, there was an excellent correlation between the specific impedance index (length 2 /impedance) and FFM (r 5 0.55, 0.62, and 0.64 for arm, trunk, and leg, respectively). The specific resistivity was in a similar range for the limbs (159 6 23 cm for the arm and 193 6 39 cm for the leg at 50 kHz) but was higher for the trunk (457 6 71 cm). This study shows the potential interest of segmental body composition by bioelectrical impedance analysis and provides specific segmental body composition equations for use in normal and overweight women. dual-energy X-ray absorptiometry; body segments; body fat; fat-free mass

No abstract

Cardiac transplantation has become a successful therapy for end-stage heart disease. However, increased bone loss has been observed in heart transplant recipients, sometimes being responsible for osteoporotic fractures. Glucocorticoids cause dose-related bone loss, particularly in the first 6-12 months of use, but cyclosporine might play a role as well. The evolution of bone mineral density (BMD) and biochemical parameters was prospectively assessed in 24 patients (mean age 52 years) from cardiac transplantation. All patients received cyclosporin A (CsA) and prednisone, the latter at decreasing dosage. The mean current daily dose of CsA was 321 mg and serum levels of CsA were constant. All patients received calcium (500 mg day-1) and vitamin D (1000 U day-1) for prevention of bone loss. BMD (gcm-2) was measured in 17 patients at the lumbar spine, femoral neck and total hip with dual energy X-ray absorptiometry every 6 months. Spinal BMD as well as neck and total hip BMD decreased at 6 and 12 months after transplantation, being statistically significant at the three sites: -5.6 and -3.4% for the lumbar spine, -9.3 and -8.5% for the femoral neck, -4.8% and -6.0% for the total hip respectively. Parathyroid hormone (PTH) and osteocalcin (BGP) increased by 90% and 800% respectively between pretransplantation values and 18 months after transplantation. BGP levels measured every 2 months from transplantation increased continuously from 8.7 micrograms L-1 (mean +/- SEM) before transplantation to 31.3 +/- 10.1 (P < 0.05) at 4 months, to 59.1 +/- 8.8 (P < 0.01) at 6 months and to 72.2 +/- 9.9 (P < 0.01) at 18 months (Kruskal-Wallis analysis: P < 0.0001). PTH showed a biphasic pattern with an initial decrease from 39.3 +/- 4.1 ng L-1 at baseline to 22.0 +/- 2.8 ng L-1 at 2 months, but increasing thereafter to 45.9 +/- 5.7 at 6 months and 74.2 +/- 8.9 at 18 months (Kruskal-Wallis analysis: P < 0.001). These variations represent a glucocorticoid-induced osteoporosis. In summary, cardiac transplant patients lose bone immediately after transplantation at the spine and the hip. Later on, the loss in BMD discontinues at all sites of the skeleton, but predominantly at the spine, and a few patients still lose bone at the hip. This is probably a result of the high bone turnover either due to secondary hyperparathyroidism or induced by cyclosporin A.

Severe respiratory insufficiency causes patients to be intolerant of physical effort and to be frequently limited in their daily activity and results in an imbalance between food intake and nutritional needs. Undernutrition and overnutrition can both affect the quality of life and survival of patients with pulmonary disease. Protein-energy malnutrition can lead to quantitative, qualitative and functional alterations of muscle [1,2] and this affects muscle function, including respiratory muscle in patients with already limited respiratory reserves. Optimal adaptation of nutrition support through the assessment of fat-free mass (FFM) and fat mass (FM) in patients with chronic respiratory insufficiency can avoid or minimize muscle wasting or obesity. For these reasons, the nutritional assessment should include body composition measurements which are based on objective rather than subjective criteria of nutritional evaluation. Body composition can be measured by a number of techniques, including hydrodensitometry, isotope dilution, and whole-body counting of potassium-40 [3]. However, these methods are not easily applicable in ill subjects.More recent methods for the determination of the FFM are dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA). DXA has been validated against independent methods, including a gamma neutronactivation model [4,5], total body potassium and hydrodensitometry [6] and is becoming one of the reference methods for body composition analysis, but requires sophisticated technology. BIA is a method of measuring body composition which is easy, noninvasive and inexpensive [7]. BIA measurements have been validated in healthy adults [8][9][10]. The relationship between body impedance and body composition is dependent on age and sex [11,12]. Over 20 different formulae permit the calculation of the FFM and FM based on BIA measurements and have generally been validated in healthy, young adults. SCHOLS et al. [13] proposed a BIA formula validated against deuterium dilution for patients with chronic obstructive pulmonary disease (COPD) (n=24), which included weight and height 2 /resistance (ht 2 /R) as independent variables. Recently, PICHARD et al. [14] were unable to obtain clinically relevant correlations between FFM calculated by 12 BIA formulae [8,9,11,[15][16][17][18][19][20][21], including SCHOLS et al. [13], and DXA-determined FFM, and suggested that a specific formula should be developed for patients with chronic severe respiratory insufficiency. These results suggest that the bioelectrical impedance analysis formula specific to patients with severe respiratory insufficiency give a better correlation and smaller mean differences than 12 different bioelectrical impedance analysis formulae described in the medical literature. A prediction equation, validated against dual-energy X-ray absorptiometry and based on subjects with similar clinical characteristics, is more applicable to the patients with respiratory insufficiency than a formula developed for healthy subje...

The glucose-induced thermogenesis (GIT) following a 100-g oral glucose load has been measured by continuous indirect calorimetry in 55 nondiabetic and diabetic obese subjects of various ages and compared with two control groups of 17 young and 13 elderly nonobese subjects. The obese subjects were divided into four groups: group A, normal glucose tolerance; group B, impaired glucose tolerance; group C, diabetes with increased insulin response; group D, diabetes with reduced insulin response. The glucose-induced thermogenesis measured during 3 h represented 8.6 ± 0.7% of the energy content of the load in the young control group. In all obese groups, the glucose-induced thermogenesis was significantly lower than in the young control group, i.e., 6.6 ± 0.9%, 6.4 ± 0.6%, 3.7 ± 0.7%, and 2.2 ± 0.4% in groups A, B, C, and D, respectively. Since the obese diabetics were older than the other groups, their glucose-induced thermogenesis was compared with that of the elderly control group; the latter (5.8 ± 0.3%) was significantly lower (P &lt; 0.05) than that of the young control group. The obese diabetics also had a significantly lower glucose-induced thermogenesis than the elderly control group (P &lt; 0.02 and P &lt; 0.001 for groups C and D, respectively). When corrected for glucosuria and after taking into account the glucosuria and the changes in the glucose space, the corrected glucose-induced thermogenesis (i.e., related to glucose “uptake”), was still significantly reduced in group A versus the young control group (6.6 ± 0.9 versus 8.6 ± 0.7%, P &lt; 0.05), and in group D versus the elderly (matched for age) control group (4.2 ± 0.7 versus 5.8 ± 0.3%, P &lt; 0.05). It is concluded that the postprandial thermogenesis induced by glucose ingestion is decreased in the presence of insulin resistance and/or reduced insulin response to the glucose load in obese subjects. In addition, age itself contributes to decrease glucose-induced thermogenesis.